PLOD3 contributes to HER-2 therapy resistance in gastric cancer through FoxO3/Survivin pathway

Human epidermal growth factor receptor 2 (HER-2), a famous therapeutic target for breast cancer, is also associated with an increased risk of recurrence and poor outcomes of other malignancies, including gastric cancer. Yet the mechanism of HER-2 therapy resistance remains controversial due to the h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yueda, Ye, Botian, Wang, Chunyan, Nie, Yanyan, Qin, Jing, Shen, Zhenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283410/
https://www.ncbi.nlm.nih.gov/pubmed/35835735
http://dx.doi.org/10.1038/s41420-022-01103-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283410/
https://www.ncbi.nlm.nih.gov/pubmed/35835735
http://dx.doi.org/10.1038/s41420-022-01103-4

Ejemplares similares